Etrasimod Emerging Drug Insight and Market Forecast - 2032

Etrasimod Emerging Drug Insight and Market Forecast − 2032

“Etrasimod Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about etrasimod for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the etrasimod for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the etrasimod for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the etrasimod market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Etrasimod (APD334) is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptor 1, 4, and 5 providing systemic and local effects on specific immune cell types. S1P is a cell surface G protein-coupled receptor (GPCR) that has been shown to regulate lymphocyte egress from lymph nodes and dendritic cell trafficking. Upon binding to S1P, synthetic modulators such as etrasimod act as functional antagonists by inducing and sustaining receptor internalization. This prevents cell migration along S1P gradients, resulting in lymphocyte retention within lymphoid tissue and a reduction in peripheral blood lymphocytes available to be recruited to inflammation sites. The drug has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn’s disease, AD, and alopecia areata.

In July 2021, the company evaluated an updated open-label extension data set from the Phase II ADVISE trial for 2 mg etrasimod in Atopic Dermatitis (AD) which demonstrated meaningful effects at week 16 of the OLE period on validated investigator global assessment at 47%, easi-75 at 72%, and peak pruritis numeric rating scale at 61% with consistent safety profile out to one year.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the etrasimod description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.

Elaborated details on etrasimod regulatory milestones and other development activities have been provided in this report.

The report also highlights the etrasimod research and development activities in atopic dermatitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around etrasimod.

The report contains forecasted sales of for atopic dermatitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.

The report also features the SWOT analysis with analyst views for etrasimod in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Etrasimod Analytical Perspective by DelveInsight

In-depth Etrasimod Market Assessment

This report provides a detailed market assessment of etrasimod for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Etrasimod Clinical Assessment

The report provides the clinical trials information of etrasimod for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence etrasimod dominance.

Other emerging products for atopic dermatitis are expected to give tough market competition to etrasimod and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of etrasimod in atopic dermatitis.

Our in-depth analysis of the forecasted sales data of etrasimod from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the etrasimod in atopic dermatitis.

Key Questions

What is the product type, route of administration and mechanism of action of etrasimod?

What is the clinical trial status of the study related to etrasimod in atopic dermatitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the etrasimod development?

What are the key designations that have been granted to etrasimod for atopic dermatitis?

What is the forecasted market scenario of etrasimod for atopic dermatitis?

What are the forecasted sales of etrasimod in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to etrasimod for atopic dermatitis?

Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?